文献速递妇科肿瘤

卵巢癌免疫治疗与放疗的合理联合

Rational combinations of immunotherapy with radiotherapy in ovarian cancer.
PubMed 文献 · Lancet Oncol · 2019-07-29

本文讨论放疗在卵巢癌中的历史与现状,阐述放疗动员抗肿瘤免疫的机制,并汇总临床前与临床数据支持免疫联合放疗,提出临床开发路线图以指导下一代临床试验。

要点

  • 大分割放疗可诱导免疫原性细胞死亡和原位疫苗效应。
  • 低于2 Gy的剂量也能重塑肿瘤微环境。
  • 需临床开发路线图指导卵巢癌免疫联合放疗试验。

核心结论

  • 放疗与免疫治疗联合在卵巢癌中具有协同控制或根除肿瘤的潜力。

研究设计与样本

  • 本文为系列综述,讨论放疗在卵巢癌中的过去与现在应用、免疫动员机制及联合治疗的临床前与临床数据。

主要发现

  • 不同剂量的大分割放疗在多种肿瘤模型中可诱导免疫原性细胞死亡和原位疫苗效应。
  • 低于2 Gy的放疗剂量也可重塑肿瘤微环境。

临床怎么用

  • 为卵巢癌免疫联合放疗的下一代临床试验提供临床开发路线图。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Except for its use in palliative care, radiotherapy has been largely abandoned in the management of ovarian cancer because of the recognised efficacy and lower toxicity of systemic chemotherapy compared with radiotherapy. New data have emerged that show synergy of radiotherapy with immunotherapy to control or eradicate cancer. Different doses of hypofractionated radiotherapy have been shown to induce immunogenic cell death and in-situ vaccination in several tumour models. However, doses less than 2 Gy can also reprogramme the tumour microenvironment. This Series paper discusses the past and present use of radiotherapy for ovarian cancer, and the mechanisms by which radiotherapy can mobilise anticancer immunity. We provide emerging preclinical and clinical data for combining immunotherapy with radiotherapy for ovarian cancer treatment and offer a clinical development roadmap to guide the next generation of clinical trials for this combination strategy for this disease.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Herrera FG, Irving M, Kandalaft LE, et al. Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncol. 2019. PMID: 31364594. doi:10.1016/S1470-2045(19)30401-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。